Interferon-a is able to maintain complete molecular remission induced by imatinib after its discontinuation Leukemia (2008) The induction of myeloblastin (MBN) expression by interferon-a (IFN-a), but not by imatinib, may contribute to the specific ability of IFN-a to induce an MBN-specific T-cell response in chronic myeloid leukemia (CML) patients. 1 We report here the clinical outcome for five CML patients who received low-dose IFN-a when CML was undetectable after imatinib. At the time of complete molecular remission (CMR) achieved by imatinib, all patients discontinued imatinib for intolerance and were 'maintained' successfully with IFN-a alone. Written informed consent was obtained from all patients.
Patient 1 was a 66-year-old woman with CML diagnosed in October 1992. She received chemotherapy and autografting. Available evidence suggests that BCR-ABL kinase inhibitor therapy (imatinib, nilotinib and dasatinib) is not curative; moreover, the risk of harboring BCR-ABL-independent leukemic cell clones might increase with the 'biologic age' of the disease. IFN-a appears to induce remissions from CML by eliciting an MBN-specific T-cell response. 4 Recent results suggest that the induction of MBN expression may be a part of this response mechanism because sole expression of tumor-specific genes in antigen-presenting cells or loading of tumor peptides onto antigen-presenting cells has been shown to induce a potent human leukocyte antigen class I-restricted, tumor-specific cytotoxic T-lymphocyte response. [5] [6] [7] Indirect evidence for a central role of MBN expression in the generation of a T-cell response is provided by the fact that all tested human leukocyte antigen-A0201 IFN-a-treated patients, but only 2 of 11 imatinibtreated patients, developed PR1-specific cytotoxic T lymphocytes. 1 This also implies that the character of remissions achieved with IFN-a and imatinib may not be equivalent and, therefore, a sequential combination therapy of imatinib and IFN-a, using their different effector mechanisms, may be more effective in the treatment of CML than any current monotherapy. The first preliminary data presented here seem to confirm the efficacy of IFN-a given to CMR patients after imatinib discontinuation.
